1. Home
  2. AGIO vs CERT Comparison

AGIO vs CERT Comparison

Compare AGIO & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$26.97

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

CERT

Certara Inc.

HOLD

Current Price

$8.61

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
CERT
Founded
2007
2008
Country
United States
United States
Employees
N/A
1546
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
AGIO
CERT
Price
$26.97
$8.61
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$32.13
$13.88
AVG Volume (30 Days)
2.7M
2.0M
Earning Date
10-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
$44,791,000.00
$415,551,000.00
Revenue This Year
$28.75
$10.82
Revenue Next Year
$139.45
$6.77
P/E Ratio
N/A
$126.84
Revenue Growth
36.26
11.47
52 Week Low
$22.24
$8.03
52 Week High
$46.00
$15.69

Technical Indicators

Market Signals
Indicator
AGIO
CERT
Relative Strength Index (RSI) 35.66 38.27
Support Level $26.80 $8.95
Resistance Level $28.61 $9.42
Average True Range (ATR) 1.15 0.39
MACD 0.28 0.06
Stochastic Oscillator 16.59 14.10

Price Performance

Historical Comparison
AGIO
CERT

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Share on Social Networks: